• Glasgow Manifesto; recorded aging webinars: IAS; Global Action on aging ICOPE
   
  
• CROI: Summary from CROI 2023 for HIV and liver disease What is new in viral hepatitis coinfection? Is fatty liver disease a growing concern? New insights from CROI 2023. - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany -
   
  
• CROI: Clinical Pharmacology at CROI 2023 - Courtney V. Fletcher, Pharm.D. Professor UNMC Center for Drug Discovery University of Nebraska Medical Center - (03/31/23)
   
  
• COVID at CDC Conference: Update on Rapid Assessment of SARS-CoV-2 Transmission at 2023 EIS Conference - (06/01/23)
   
  
• COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022 - (05/30/23)
   
  
• LENACAPAVIR DISRUPTS HIV-1 CORE INTEGRITY WHILE STABILIZING THE CAPSID LATTICE - (05/30/23)
   
  
• Population-PK Analysis to Guide Dosing Window Following Lenacapavir SC Administration - (05/30/23)
   
  
• CROI: NO ANTAGONISM OR CROSS-RESISTANCE OBSERVED BETWEEN ISLATRAVIR AND LENACAPAVIR - (05/30/23)
   
  
More HIV Articles...
 

• HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
   
  
• Updated Prevalence of Chronic Hepatitis B and Hepatitis Delta Infection Among Foreign-Born Individuals in the United States (Global Hepatitis Summit 2023, Paris April 28) - (04/29/23)
   
  
More Hep D Articles...
 


---


 
Aging & Perinatally HIV Infected
 

• PWH had a higher prevalence of AD (alzheimers)/ADRD. PWH had a higher burden of dementia - (06/05/23)
   
  
• Impact of Multiple Social Determinants of Health on Incident Stroke - (06/05/23)
   
  
• Stroke Incidence among White, Black, and Hispanic Residents of an Urban Community - (06/05/23)
   
  
• Daily statin medication was found to reduce the risk of cardiovascular disease by 35% among people living with HIV; substantial CVD risk in Young PWH - REPRIEVE Study - (06/05/23)
   
  
More Aging & HIV Articles...
 


---


 
Mpox
 

• Several cases of Apparent Mpox Reinfection in Europe - (05/29/23)
   
  
• Fact Sheet: HHS Provides Resources on Ways Communities Can Stay Protected from Mpox in Advance of Summer Months - (05/25/23)
   
  
More Monkeypox Articles...
 

• Global HCV Cascade No Progress/Worse Liver Deaths/HCC Increase Expected 2015-2020 Modelling
  Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study - (06/05/23)
   
  
• CDC New Increasing HCV Cases 2019-2020 Rates by State - (06/01/23)
   
  
• Updated HCV Maternal Infection Rates - (05/23/23)
   
  
• A Proclamation on National Hepatitis Testing Day, 2023 by Pres. Biden - (05/22/23)
   
  
• NYS HCV Treatment OTPs Billing Guide - (05/19/23)
   
  
• HCV DAAs During Pregnancy - (05/17/23)
   
  
More Hep C Articles...
 

• HBV Patient Declaration of Rights - (05/15/23)
   
  
• HBV Treatment Reduces HCC. Editorial: Re-assessing antiviral treatment criteria for chronic hepatitis B - (06/01/23)
   
  
• FULMINANT HEPATITIS B AFTER SWITCH IN ANTIRETROVIRAL THERAPY - (05/24/23)
   
  
• Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals - (05/12/23)
   
  
• Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI - (05/12/23)
   
  
More Hep B Articles...
 


---


 
Fatty Liver, NAFLD, NASH
 

• Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH - (06/01/23)
   
  
• Evolving NAFLD Models of Care & Future Perspectives - Prof. Jeffrey Lazarus (Global Hepatitis Summit 2023 April 28 Paris) - (05/08/23)
   
  
• INTERCEPT ANNOUNCES FDA ADVISORY COMMITTEE MEETING DATE FOR OBETICHOLIC ACID AS A TREATMENT FOR PRE-CIRRHOTIC LIVER FIBROSIS DUE TO NASH PRESS RELEASE - (03/14/23)
   
  
• CROI: PREVALENCE AND FACTORS ASSOCIATED WITH NAFLD IN PEOPLE WITH HIV - (02/21/23)
   
  
• CROI: CONTROLLED ATTENUATION PARAMETER IS A VISCERAL ADIPOSITY MARKER IN HIV-RELATED NAFLD - (02/21/23)
   
  
• CROI: SEX DIFFERENCES IN THE ASSOCIATION OF HIV WITH METABOLIC-FATTY LIVER DISEASE - (02/21/23)
   
  
• CROI: NAFLD AND ITS COMBINATION WITH NASH PREDICT DM DEVELOPMENT IN PEOPLE WITH HIV - (02/21/23)
   
  
• CROI: LIVER STEATOSIS AND FIBROSIS IN WOMEN WITH HIV BY INTEGRASE INHIBITOR USE - (02/21/23)
   
  
More Fatty Liver Articles...
 

List not necessarily listed here in order of date being held.